GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Align Technology Inc (NAS:ALGN) » Definitions » Debt-to-EBITDA

Align Technology (Align Technology) Debt-to-EBITDA : 0.17 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Align Technology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Align Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $31 Mil. Align Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $95 Mil. Align Technology's annualized EBITDA for the quarter that ended in Mar. 2024 was $748 Mil. Align Technology's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Align Technology's Debt-to-EBITDA or its related term are showing as below:

ALGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.1   Med: 0.16   Max: 0.18
Current: 0.16

During the past 13 years, the highest Debt-to-EBITDA Ratio of Align Technology was 0.18. The lowest was 0.10. And the median was 0.16.

ALGN's Debt-to-EBITDA is ranked better than
82.63% of 426 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs ALGN: 0.16

Align Technology Debt-to-EBITDA Historical Data

The historical data trend for Align Technology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Align Technology Debt-to-EBITDA Chart

Align Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.18 0.12 0.16 0.16

Align Technology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.16 0.16 0.15 0.17

Competitive Comparison of Align Technology's Debt-to-EBITDA

For the Medical Devices subindustry, Align Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Align Technology's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Align Technology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Align Technology's Debt-to-EBITDA falls into.



Align Technology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Align Technology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(29.651 + 96.968) / 799.055
=0.16

Align Technology's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(31.324 + 95.092) / 748.324
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Align Technology  (NAS:ALGN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Align Technology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Align Technology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Align Technology (Align Technology) Business Description

Traded in Other Exchanges
Address
410 North Scottsdale Road, Suite 1300, Tempe, AZ, USA, 85281
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the FDA in 1998, and it has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans and iTero scans make up over half of these scans.
Executives
Joseph M Hogan director, officer: President and CEO C/O ALIGN TECHNOLOGY, INC., 410 NORTH SCOTTSDALE ROAD, SUITE 1300, TEMPE AZ 85281
Kevin J Dallas director C/O ALIGN TECHNOLOGY INC., 2560 ORCHARD PARKWAY, SAN JOSE CA 95134
John Morici officer: Chief Financial Officer C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Anne Myong director 2820 ORCHARD PARKWAY, SAN JOSE CA 95141
Warren S Thaler director C/O ALIGN TECHNOLOGY, INC., 410 NORTH SCOTTSDALE ROAD, SUITE 1300, TEMPE AZ 85281
Larkin C Raymond Jr director C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105
Julie Ann Coletti officer: SVP, Chief Legal & Regulatory 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Greg J Santora director 4201 GRANT COURT, PLEASANTON CA 94566
Stuart A Hockridge officer: VP, Global Human Resources C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Emory Wright officer: VP, Operations C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
George J Morrow director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Andrea Lynn Saia director C/O COCA-COLA ENTERPRISES, INC., 2500 WINDY RIDGE PARKWAY, NW, 14TH FLOOR, ATLANTA GA 30339
Thomas M Prescott director C/O ALIGN TECHNOLOGY INC, 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Yuval Shaked officer: SVP and Mgng Director, Itero C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 95134
Jennifer Olson officer: VP& Mng Dir. D-DCC C/O ALIGN TECHNOLOGY, INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131